Liver drug bulevirtide tested in people with liver problems

NCT ID NCT05765344

Completed Knowledge-focused Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants and aimed to understand dosing needs for patients with liver issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bulevirtide (also known as Hepcludex or Myrcludex B)
What this could lead to: If successful, this study could help doctors determine the right dose of bulevirtide for patients with liver problems.
What could go wrong: This is an early Phase 1 study focused on drug levels, not on treating disease. It may not lead to any new treatment or change in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS D INFECTION HEALTHY HEPATIC IMPAIRMENT

Contacts and locations

Locations

Clinical Pharmacology of Miami, LLC

Miami, Florida, 33014, United States
Orange County Research Center

Lake Forest, California, 92630, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Pinnacle Clinical Research LLC

San Antonio, Texas, 78229, United States
Texas Liver Institute

San Antonio, Texas, 78215, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.